Trial Profile
A Multi-Center, Randomized, Placebo-Controlled, Phase 1, Two-Part Study Designed to Assess the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Posenacaftor (Primary) ; Dirocaftor
- Indications Cystic fibrosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Proteostasis Therapeutics
- 28 Apr 2020 Status changed from recruiting to completed.
- 22 Jan 2020 Planned End Date changed from 1 Dec 2019 to 31 Mar 2020.
- 22 Jan 2020 Planned primary completion date changed from 1 Dec 2019 to 31 Mar 2020.